Alan Burnett
Projects as PI
2 of 5
- AML 16 being a National Cancer Research Institute Acute Myeloid Leukaemia and High Risk MDS Trial (06/08/2010 - 31/07/2013)
- AML17: A trial of development of the Myeloid Leukaemia and high risk Myelodysplastic Syndrome in younger patients (01/08/2008 - 31/07/2014)
- AML 17 being an acute myeloid leukaemia or high risk myelodysplastic syndrome multi-site randomised trial (01/02/2009 - 31/01/2012)
- AML 18 pilot (23/05/2011 - 22/11/2012)
- A phase 1B/2 study to evaluate the feasibility of combining either the tyrosine kinase inhibitor AC220 or the CXCR4 inhibitor Plerixafor with chemotherapy in older patients with acute myeloid leukaemia and myelodysplastic syndrome in patients over 60 (01/06/2011 - 31/12/2013)
Projects as Co-Investigator
1 of 2
- Cancer Genetics Biomedical Research Unit (31/03/2011 - 31/05/2015)
- CD200: A putative target of AML (01/12/2008 - 30/11/2011)
- Clinical Hubs for phase 1 of the Cancer Research UK stratified medicine programme (01/07/2011 - 30/09/2022)
- Identification of therapeutic targets in acute myeloid leukaemia expressing the mutant RAS oncogene (31/03/2010 - 31/03/2014)
- Investigation of the role of RAL dysregulation in myeloid leukaemia (01/11/2008 - 31/10/2011)
